Johnson & Johnson (JNJ): Price and Financial Metrics

Johnson & Johnson (JNJ)

Today's Latest Price: $123.16 USD

3.41 (-2.69%)

Updated Mar 27 12:00am

Add JNJ to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

JNJ Stock Summary

  • JNJ has a market capitalization of $313,666,552,513 -- more than approximately 99.82% of US stocks.
  • JNJ's went public 34.26 years ago, making it older than 92.67% of listed US stocks we're tracking.
  • In terms of volatility of its share price, JNJ is more volatile than merely 3.02% of stocks we're observing.
  • Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are WMT, JPM, PG, TSM, and MA.
  • Visit JNJ's SEC page to see the company's official filings. To visit the company's web site, go to
JNJ Daily Price Range
JNJ 52-Week Price Range

JNJ Stock Price Chart More Charts

JNJ Price/Volume Stats

Current price $123.16 52-week high $154.50
Prev. close $126.57 52-week low $109.16
Day low $120.58 Volume 12,133,200
Day high $127.62 Avg. volume 10,267,655
50-day MA $141.56 Dividend yield 3.09%
200-day MA $136.69 Market Cap 324.69B

Johnson & Johnson (JNJ) Company Bio

Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.

JNJ Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for JNJ, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Johnson & Johnson ranked in the 30th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 35.33%. In terms of the factors that were most noteworthy in this DCF analysis for JNJ, they are:

  • The company has produced more trailing twelve month cash flow than 98.48% of its sector Healthcare.
  • The business' balance sheet reveals debt to be 8% of the company's capital (with equity being the remaining amount). Approximately only 17.63% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 49.65% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as JNJ, try HBIO, GSK, HSIC, PDLI, and SGRY.

JNJ Latest News Stream

Event/TimeNews Detail
Loading, please wait...

JNJ Latest Social Stream

Loading social stream, please wait...

View Full JNJ Social Stream

JNJ Price Returns

1-mo -8.42%
3-mo -15.03%
6-mo -5.45%
1-year -9.44%
3-year 7.12%
5-year 42.41%
YTD -15.03%
2019 16.22%
2018 -5.13%
2017 24.43%
2016 15.33%
2015 1.14%

JNJ Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7718 seconds.